Cancer cell-autonomous TRAIL-R signaling promotes KRAS-Driven cancer progression, invasion, and metastasis

Cancer Cell

Volumn 27, Issue 4, 2015, Pages 561-573

  von Karstedt, Silvia ^a   Conti, Annalisa ^a,b   Nobis, Max ^c   Montinaro, Antonella ^a   Hartwig, Torsten ^a   Lemke, Johannes ^a   Legler, Karen ^d   Annewanter, Franka ^d   Campbell, Andrew D ^c   Taraborrelli, Lucia ^a   Grosse Wilde, Anne ^e,f   Coy, Johannes F ^e,g   El Bahrawy, Mona A ^h   Bergmann, Frank ⁱ   Koschny, Ronald ⁱ   Werner, Jens ⁱ   Ganten, Tom M ⁱ   Schweiger, Thomas ^j   Hoetzenecker, Konrad ^j   Kenessey, Istvan ^k   Hegedüs, Balazs ^j,l   Bergmann, Michael ^j   Hauser, Charlotte ^m   Egberts, Jan Hendrik ^m   Becker, Thomas ^m   Röcken, Christoph ^d   Kalthoff, Holger ^d   Trauzold, Anna ^d,m   Anderson, Kurt I ^c   Sansom, Owen J ^c   Walczak, Henning ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF KIEL   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^g Darmstadt and Tavargenix GmbH   (Germany)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k SEMMELWEIS UNIVERSITY   (Hungary)

^l INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^m UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; RAC1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH VESSEL; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DISEASE COURSE; GENETICS; METABOLISM; PANCREAS CARCINOMA; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SCID MOUSE; TUMOR CELL LINE;

MURINAE;

ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84928080746     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.02.014     Document Type: Article

References (70)

1. Ali I.U., Schriml L.M., Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J.Natl. Cancer Inst. 1999, 91:1922-1932.
2. Aoki K., Matsuda M. Visualization of small GTPase activity with fluorescence resonance energy transfer-based biosensors. Nat. Protoc. 2009, 4:1623-1631.
3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J.Clin. Invest. 1999, 104:155-162.
4. Azijli K., Yuvaraj S., Peppelenbosch M.P., Würdinger T., Dekker H., Joore J., van Dijk E., Quax W.J., Peters G.J., de Jong S., Kruyt F.A. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J.Cell Sci. 2012, 125:4651-4661.
5. Baines A.T., Xu D., Der C.J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 2011, 3:1787-1808.
6. Balmain A., Ramsden M., Bowden G.T., Smith J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 1984, 307:658-660.
7. Belyanskaya L.L., Ziogas A., Hopkins-Donaldson S., Kurtz S., Simon H.U., Stahel R., Zangemeister-Wittke U. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung Cancer 2008, 60:355-365.
8. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
9. Castellano E., Sheridan C., Thin M.Z., Nye E., Spencer-Dene B., Diefenbacher M.E., Moore C., Kumar M.S., Murillo M.M., Grönroos E., et al. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 2013, 24:617-630.
10. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis inTNF-related apoptosis-inducing ligand-deficient mice. J.Immunol. 2002, 168:1356-1361.
11. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'En P., Xu X.N., Jin B.Q., Pezzella F., Screaton G.R. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005, 15:430-438.
12. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997, 7:813-820.
13. Downward J. Targeting RAS and PI3K in lung cancer. Nat. Med. 2008, 14:1315-1316.
14. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008, 68:1443-1450.
15. Ehrhardt H., Fulda S., Schmid I., Hiscott J., Debatin K.M., Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003, 22:3842-3852.
16. Elrod H.A., Fan S., Muller S., Chen G.Z., Pan L., Tighiouart M., Shin D.M., Khuri F.R., Sun S.Y. Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. PLoS ONE 2010, 5:e12178.
17. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
18. Finnberg N., Klein-Szanto A.J., El-Deiry W.S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J.Clin. Invest. 2008, 118:111-123.
19. Fritsch R., de Krijger I., Fritsch K., George R., Reason B., Kumar M.S., Diefenbacher M., Stamp G., Downward J. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013, 153:1050-1063.
20. Ganten T.M., Sykora J., Koschny R., Batke E., Aulmann S., Mansmann U., Stremmel W., Sinn H.P., Walczak H. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J.Mol. Med. (Berl.) 2009, 87:995-1007.
21. Grady W.M., Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 2002, 3:101-128.
22. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., Csernok A.I., Schütz G., Greiner E.F., Kemp C.J., Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J.Clin. Invest. 2008, 118:100-110.
23. Gupta S., Ramjaun A.R., Haiko P., Wang Y., Warne P.H., Nicke B., Nye E., Stamp G., Alitalo K., Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
24. Harper N., Farrow S.N., Kaptein A., Cohen G.M., MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J.Biol. Chem. 2001, 276:34743-34752.
25. Haselmann V., Kurz A., Bertsch U., Hübner S., Olempska-Müller M., Fritsch J., Häsler R., Pickl A., Fritsche H., Annewanter F., et al. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology 2014, 146:278-290.
26. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from invivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9:690-701.
27. Heid I., Lubeseder-Martellato C., Sipos B., Mazur P.K., Lesina M., Schmid R.M., Siveke J.T. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 2011, 141:719-730. 730.e1-7.
28. Hidalgo M. Pancreatic cancer. N.Engl. J. Med. 2010, 362:1605-1617.
29. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
30. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
31. Hodgson L., Shen F., Hahn K. Biosensors for characterizing the dynamics of rho family GTPases in living cells. Curr. Protoc. Cell Biol. 2010, Chapter 14. Unit 14.11.1-14.11.26.
32. Hoogwater F.J., Nijkamp M.W., Smakman N., Steller E.J., Emmink B.L., Westendorp B.F., Raats D.A., Sprick M.R., Schaefer U., Van Houdt W.J., et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010, 138:2357-2367.
33. Ishimura N., Isomoto H., Bronk S.F., Gores G.J. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G129-G136.
34. Itoh R.E., Kurokawa K., Ohba Y., Yoshizaki H., Mochizuki N., Matsuda M. Activation of rac and cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes in the membrane of living cells. Mol. Cell. Biol. 2002, 22:6582-6591.
35. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
36. Jaffee E.M., Hruban R.H., Canto M., Kern S.E. Focus on pancreas cancer. Cancer Cell 2002, 2:25-28.
37. Johnsson A.K., Dai Y., Nobis M., Baker M.J., McGhee E.J., Walker S., Schwarz J.P., Kadir S., Morton J.P., Myant K.B., et al. The Rac-FRET mouse reveals tight spatiotemporal control of Rac activity in primary cells and tissues. Cell Rep. 2014, 6:1153-1164.
38. Kasinski A.L., Slack F.J. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012, 72:5576-5587.
39. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
40. Kischkel F.C., Lawrence D.A., Tinel A., LeBlanc H., Virmani A., Schow P., Gazdar A., Blenis J., Arnott D., Ashkenazi A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J.Biol. Chem. 2001, 276:46639-46646.
41. Kissil J.L., Walmsley M.J., Hanlon L., Haigis K.M., Bender Kim C.F., Sweet-Cordero A., Eckman M.S., Tuveson D.A., Capobianco A.J., Tybulewicz V.L., Jacks T. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res. 2007, 67:8089-8094.
42. Koschny R., Holland H., Sykora J., Haas T.L., Sprick M.R., Ganten T.M., Krupp W., Bauer M., Ahnert P., Meixensberger J., Walczak H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. 2007, 13:3403-3412.
43. Kraynov V.S., Chamberlain C., Bokoch G.M., Schwartz M.A., Slabaugh S., Hahn K.M. Localized Rac activation dynamics visualized in living cells. Science 2000, 290:333-337.
44. Lambert J.M., Lambert Q.T., Reuther G.W., Malliri A., Siderovski D.P., Sondek J., Collard J.G., Der C.J. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat. Cell Biol. 2002, 4:621-625.
45. Lemke J., Noack A., Adam D., Tchikov V., Bertsch U., Röder C., Schütze S., Wajant H., Kalthoff H., Trauzold A. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J.Mol. Med. 2010, 88:729-740.
46. Lemke J., von Karstedt S., Zinngrebe J., Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014, 21:1350-1364.
47. Ling J., Kang Y., Zhao R., Xia Q., Lee D.F., Chang Z., Li J., Peng B., Fleming J.B., Wang H., et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
48. Macher-Goeppinger S., Aulmann S., Tagscherer K.E., Wagener N., Haferkamp A., Penzel R., Brauckhoff A., Hohenfellner M., Sykora J., Walczak H., et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 2009, 15:650-659.
49. Mack N.A., Porter A.P., Whalley H.J., Schwarz J.P., Jones R.C., Khaja A.S., Bjartell A., Anderson K.I., Malliri A. β2-syntrophin and Par-3 promote an apicobasal Rac activity gradient at cell-cell junctions by differentially regulating Tiam1 activity. Nat. Cell Biol. 2012, 14:1169-1180.
50. Mitsuuchi Y., Testa J.R. Cytogenetics and molecular genetics of lung cancer. Am. J. Med. Genet. 2002, 115:183-188.
51. Morton J.P., Timpson P., Karim S.A., Ridgway R.A., Athineos D., Doyle B., Jamieson N.B., Oien K.A., Lowy A.M., Brunton V.G., et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010, 107:246-251.
52. Myant K.B., Cammareri P., McGhee E.J., Ridgway R.A., Huels D.J., Cordero J.B., Schwitalla S., Kalna G., Ogg E.L., Athineos D., et al. ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 2013, 12:761-773.
53. Nimnual A.S., Yatsula B.A., Bar-Sagi D. Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos. Science 1998, 279:560-563.
54. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
55. Ozawa F., Friess H., Kleeff J., Xu Z.W., Zimmermann A., Sheikh M.S., Büchler M.W. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001, 163:71-81.
56. Ritsma L., Steller E.J.A., Ellenbroek S.I.J., Kranenburg O., Borel Rinkes I.H., van Rheenen J. Surgical implantation of an abdominal imaging window for intravital microscopy. Nat. Protoc. 2013, 8:583-594.
57. Sanlioglu A.D., Koksal I.T., Ciftcioglu A., Baykara M., Luleci G., Sanlioglu S. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J.Urol. 2007, 177:359-364.
58. Sanz-Moreno V., Marshall C.J. The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr. Opin. Cell Biol. 2010, 22:690-696.
59. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
60. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
61. Sotillo R., Schvartzman J.M., Socci N.D., Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 2010, 464:436-440.
62. Spierings D.C., de Vries E.G., Timens W., Groen H.J., Boezen H.M., de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin. Cancer Res. 2003, 9:3397-3405.
63. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609.
64. Sprick M.R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M.A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002, 21:4520-4530.
65. Steffen A., Ladwein M., Dimchev G.A., Hein A., Schwenkmezger L., Arens S., Ladwein K.I., Margit Holleboom J., Schur F., Victor Small J., et al. Rac function is crucial for cell migration but is not required for spreading and focal adhesion formation. J.Cell Sci. 2013, 126:4572-4588.
66. Todaro M., Lombardo Y., Francipane M.G., Alea M.P., Cammareri P., Iovino F., Di Stefano A.B., Di Bernardo C., Agrusa A., Condorelli G., et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008, 15:762-772.
67. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Röder C., Kalthoff H., Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25:7434-7439.
68. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J.Biol. Chem. 2005, 280:40599-40608.
69. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand invivo. Nat. Med. 1999, 5:157-163.
70. Wu G.S., Burns T.F., Zhan Y., Alnemri E.S., El-Deiry W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 1999, 59:2770-2775.